Elevation of the Acid Phosphatase in Benign Prostatic Disease

Howard, Patrick; Fraley, Elwin E.

doi:10.1016/s0022-5347(17)63701-7

Cited by 31 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5% showed untypically increased values up to 4.5 ng/ml for the RIA and up to 3.0 ng/ml for the EIA, although clinically carcinoma was ruled out by prostate biopsy. These findings can be well explained by areas o f infarction associ ated with areas of cellular necrosis, often found with benign prostatic hypertrophy [ 17], On the basis of 95% percentile we arbi trarily defined our normal range for RIA with up to 2.5 ng/ml and for EIA with up to 1.4 ng/ml. We intentionally calculated false positive results in 5% o f non-carcinoma pa tients.…”

Section: Resultsmentioning

confidence: 87%

Clinical Value of Different Methods for Determination of Acid Phosphatase in Prostatic Cancer

Flüchter¹,

Bichler²,

Harzmann³

et al. 1982

Urol Int

View full text Add to dashboard Cite

The availability of a radioimmunoassay (RIA) and an enzyme immunoassay (EIA) for the prostate specific acid phosphatase required a study to compare these techniques with the conventional colorimetric assay. Our study is based on examinations of 188 normal persons and 136 patients with carcinoma of the prostate. The advantage of the immunologic methods – RIA and EIA – lies in their stable immunologic activity and their high specificity. However, RIA and EIA are not screening methods for incidental carcinoma because of their low sensitivity for stage-A tumors. Their good sensitivity at lower ranges of concentration makes them suitable for checking the course of a prostatic carcinoma during therapy. The level of prostatic acid phosphatase may allow conclusions about intra-or extracapsular growth of the prostatic carcinoma.

show abstract

Section: Resultsmentioning

confidence: 87%

Clinical Value of Different Methods for Determination of Acid Phosphatase in Prostatic Cancer

Flüchter¹,

Bichler²,

Harzmann³

et al. 1982

Urol Int

View full text Add to dashboard Cite

show abstract

“…Several investigators have also noted an association between prostatic infarcts and prostatic hyperplasia with a reported incidence ranging from 17.8% to 25% [11,12]. Prostatic infarcts have been shown to elevate serum prostatic acid phosphatase levels by enzymatic and immunoradiometric assay [13][14][15][16]. Recently, Brawn et al [4] demonstrated that prostatic infarcts elevate PSA levels more frequently than prostatic acid phosphatase (PAP) levels and that prostatic infarcts may be responsible for unexplained elevations of serum PSA seen in some patients [4].…”

Section: Discussionmentioning

confidence: 99%

Ischemic damage to the prostate during cardiac surgery: A clinical model

et al. 1997

View full text Add to dashboard Cite

“…Six of the 13 cases without prostatic cancer but with raised serum AcPase activities had rectal examination performed within two hours of the blood being drawn or were catheterized at that time. By inducing infarction of an enlarged prostate, catheterization may lead to gross transient elevations of serum AcPase (Howard and Fraley, 1965). Hock and Tessier (1949) reported elevation of the serum AcPase above the initial value in 17 of 20 patients undergoing rectal examination.…”

Section: Subjects With Prostatic Cancermentioning

confidence: 99%

An assessment of serum acid and alkaline phosphatase determinations in prostatic cancer with a clinical validation of an acid phosphatase assay utilizing adenosine 3′ -monophosphate as substrate

Goldberg¹,

Ellis²

1974

J Clin Pathol

View full text Add to dashboard Cite

SYNOPSIS Serum acid phosphatase (AcPase) was measured by a colorimetric method utilizing adenosine 3'-monophosphate as substrate in 389 patients. In about half the cases blood was taken shortly after a rectal examination. The upper reference limit (mean + 2SD) for 116 cases with miscellaneous illness after eliminating outliers was 4f1 International Units per litre (U/I) at 37°C, and no correlation existed between AcPase activity and age in these subjects (r = 0 040). Eight of 18 patients with untreated carcinoma confined within the prostate gland had AcPase activities below 4-1 U/1, and all of 27 cases with extension to pelvic soft tissues or to bone exceeded this value. AcPase activities above 4f1 U/l were found in 6% of cases with benign hypertrophy of the prostate, in 5% of cases with non-prostatic cancer, and in none of 22 cases with other urological illness.Raised serum alkaline phosphatase (APase) activity was found in 60% of patients with untreated prostatic cancer and in only 6% of patients free of prostatic cancer, in most of whom there was a clinical explanation for the elevation. The correlation between the two phosphatase activities was not significant (r = 0.294). While APase activity does not reflect the stage of the disease as closely as AcPase activity, and is not so frequently elevated, it provided useful confirmation of the diagnosis in five patients of the present series whose AcPase levels were normal or only minimally elevated.

show abstract

Elevation of the Acid Phosphatase in Benign Prostatic Disease

Cited by 31 publications

References 16 publications

Clinical Value of Different Methods for Determination of Acid Phosphatase in Prostatic Cancer

Clinical Value of Different Methods for Determination of Acid Phosphatase in Prostatic Cancer

Ischemic damage to the prostate during cardiac surgery: A clinical model

An assessment of serum acid and alkaline phosphatase determinations in prostatic cancer with a clinical validation of an acid phosphatase assay utilizing adenosine 3′ -monophosphate as substrate

Contact Info

Product

Resources

About